Lori Leslie, MD
Medical Oncology · Hackensack, NJNPI 1972746394
Payments from drug & device makers
Across 1,569 payments — averaging $7574.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3.1M
- Beigene, Ltd.$2.5M
- Genmab A/s$1.7M
- Acerta Pharma LLC$1.1M
- Beigene AUS Pty Ltd$651K
- Regeneron$539K
- plus $2.3M from 26 others
Across 7 payments — averaging $188.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1K
- TG Therapeutics, Inc.$16
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 363 | $3,145,317 |
| Beigene, Ltd. | 64 | $2,505,175 |
| Genmab A/s | 312 | $1,733,519 |
| Acerta Pharma LLC | 13 | $1,058,608 |
| Beigene AUS Pty Ltd | 164 | $650,961 |
| Regeneron | 77 | $538,560 |
| Eli Lilly | 8 | $449,331 |
| TG Therapeutics, Inc. | 111 | $309,859 |
| Bristol Myers Squibb | 18 | $300,969 |
| AbbVie | 59 | $277,882 |
| Novartis | 6 | $190,474 |
| AstraZeneca | 59 | $156,269 |
| Beigene USA, Inc. | 77 | $133,806 |
| Beone Medicines Ltd. | 16 | $63,581 |
| Lilly USA, LLC | 32 | $62,665 |
| Seagen Inc. | 56 | $62,430 |
| Epizyme, Inc. | 29 | $59,579 |
| Merck | 4 | $58,366 |
| Pharmacyclics LLC, An Abbvie Company | 37 | $33,976 |
| Johnson & Johnson | 19 | $29,940 |
| Genmab U.S., Inc. | 18 | $22,141 |
| Janssen Research & Development, LLC | 2 | $15,050 |
| Genentech, Inc. | 6 | $8,893 |
| Janssen Scientific Affairs, LLC | 2 | $4,973 |
| Beone Medicines USA, Inc. | 2 | $3,900 |
| ADC Therapeutics America, Inc. | 1 | $2,800 |
| Karyopharm Therapeutics Inc. | 3 | $1,966 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,867 |
| Adaptive Biotechnologies Corporation | 2 | $896 |
| Genentech USA, Inc. | 4 | $152 |
| Secura Bio, Inc. | 1 | $146 |
| Daiichi Sankyo Inc. | 1 | $15 |
How this compares
$11,884,064 in reported general payments places this provider in the 95th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Hackensack
- Martin GutierrezHackensack$41.8M
- James McCloskeyHackensack$17.1M
- Tatyana FeldmanHackensack$8.4M
- David SiegelHackensack$6.9M
- Noa BiranHackensack$5.8M
- Andrew PecoraHackensack$4.5M
- Robert AlterHackensack$4.5M
- Jamie KoprivnikarHackensack$3.8M
- David VesoleHackensack$3M
- Deena GrahamHackensack$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.